Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment
Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment
Background: Long-term treatment for atopic dermatitis (AD) using low dose, intermittent, topical anti-inflammatory agents may control acute disease and prevent relapses. This 12-month, European, multicentre, randomized study investigated whether the proactive use of 0.1% tacrolimus ointment applied twice weekly can keep AD in remission and reduce the incidence of disease exacerbations (DE).
Methods: During the initial open-label period, 257 adults with AD applied 0.1% tacrolimus ointment twice daily (b.i.d.) for up to 6 weeks to affected areas. When an Investigator Global Assessment (IGA) score of ?2 was achieved, the patient entered the disease control period (DCP) and was randomized to either proactive tacrolimus (n = 116) or vehicle ointment (n = 108) twice weekly for 12 months. Exacerbations were treated with 0.1% tacrolimus ointment b.i.d. until an IGA ?2 was regained, then randomized treatment was restarted. The primary endpoint was the number of DEs during the DCP that required a substantial therapeutic intervention.
Results: Proactive tacrolimus 0.1% ointment application significantly reduced the number of DEs requiring substantial therapeutic intervention (median difference 2; P < 0.001; Wilcoxon rank sum test), the percentage of DE treatment days (median difference: 15.2%; P < 0.001; Wilcoxon rank sum test) and increased the time to first DE (median 142 vs 15 days; P < 0.001; stratified log-rank test). The adverse event profile was similar for the two treatment approaches.
Conclusion: A 12-month, twice weekly proactive tacrolimus ointment application was an effective treatment in most study patients which prevented, delayed and reduced the occurrence of AD exacerbations.
adults, atopic dermatitis, disease control, proactive therapy, 0.1% tacrolimus ointment
742-750
Wollenbeurg, A.
331d4fca-0ec9-44ef-9f1f-0d426a512e45
Reitamo, S.
de682814-ac1b-40e1-846c-ec6eac69f33c
Girolomoni, G.
c39897b7-64a6-40a1-b0aa-1d460fd3337d
Lahfa, M.
6be719a1-8694-4291-9389-609b33978e86
Ruzicka, T.
b2c651a6-3c36-4f40-957e-a7bf71fa7271
Healy, E.
400fc04d-f81a-474a-ae25-7ff894be0ebd
Gianetti, A.
eadee0b2-68e6-4b79-8a11-5d5eec920185
Bieber, T.
b55a872a-62c0-4e7c-bc84-11df03fb087f
Vyas, J.
791b395c-df95-4b0d-9b47-2a81a08d2e52
Deleuran, M.
e0047531-94b0-4183-be54-efbb5a848b05
European Tacrolimus Ointment Study Group
July 2008
Wollenbeurg, A.
331d4fca-0ec9-44ef-9f1f-0d426a512e45
Reitamo, S.
de682814-ac1b-40e1-846c-ec6eac69f33c
Girolomoni, G.
c39897b7-64a6-40a1-b0aa-1d460fd3337d
Lahfa, M.
6be719a1-8694-4291-9389-609b33978e86
Ruzicka, T.
b2c651a6-3c36-4f40-957e-a7bf71fa7271
Healy, E.
400fc04d-f81a-474a-ae25-7ff894be0ebd
Gianetti, A.
eadee0b2-68e6-4b79-8a11-5d5eec920185
Bieber, T.
b55a872a-62c0-4e7c-bc84-11df03fb087f
Vyas, J.
791b395c-df95-4b0d-9b47-2a81a08d2e52
Deleuran, M.
e0047531-94b0-4183-be54-efbb5a848b05
Wollenbeurg, A., Reitamo, S., Girolomoni, G., Lahfa, M., Ruzicka, T., Healy, E., Gianetti, A., Bieber, T., Vyas, J. and Deleuran, M.
,
European Tacrolimus Ointment Study Group
(2008)
Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment.
Allergy, 63 (7), .
(doi:10.1111/j.1398-9995.2008.01683.x).
(PMID:18445188)
Abstract
Background: Long-term treatment for atopic dermatitis (AD) using low dose, intermittent, topical anti-inflammatory agents may control acute disease and prevent relapses. This 12-month, European, multicentre, randomized study investigated whether the proactive use of 0.1% tacrolimus ointment applied twice weekly can keep AD in remission and reduce the incidence of disease exacerbations (DE).
Methods: During the initial open-label period, 257 adults with AD applied 0.1% tacrolimus ointment twice daily (b.i.d.) for up to 6 weeks to affected areas. When an Investigator Global Assessment (IGA) score of ?2 was achieved, the patient entered the disease control period (DCP) and was randomized to either proactive tacrolimus (n = 116) or vehicle ointment (n = 108) twice weekly for 12 months. Exacerbations were treated with 0.1% tacrolimus ointment b.i.d. until an IGA ?2 was regained, then randomized treatment was restarted. The primary endpoint was the number of DEs during the DCP that required a substantial therapeutic intervention.
Results: Proactive tacrolimus 0.1% ointment application significantly reduced the number of DEs requiring substantial therapeutic intervention (median difference 2; P < 0.001; Wilcoxon rank sum test), the percentage of DE treatment days (median difference: 15.2%; P < 0.001; Wilcoxon rank sum test) and increased the time to first DE (median 142 vs 15 days; P < 0.001; stratified log-rank test). The adverse event profile was similar for the two treatment approaches.
Conclusion: A 12-month, twice weekly proactive tacrolimus ointment application was an effective treatment in most study patients which prevented, delayed and reduced the occurrence of AD exacerbations.
This record has no associated files available for download.
More information
e-pub ahead of print date: 25 April 2008
Published date: July 2008
Keywords:
adults, atopic dermatitis, disease control, proactive therapy, 0.1% tacrolimus ointment
Organisations:
Infection Inflammation & Immunity
Identifiers
Local EPrints ID: 73142
URI: http://eprints.soton.ac.uk/id/eprint/73142
ISSN: 0105-4538
PURE UUID: 6d30b745-8a38-44b9-b3ea-5872bfd89e41
Catalogue record
Date deposited: 02 Mar 2010
Last modified: 13 Mar 2024 21:55
Export record
Altmetrics
Contributors
Author:
A. Wollenbeurg
Author:
S. Reitamo
Author:
G. Girolomoni
Author:
M. Lahfa
Author:
T. Ruzicka
Author:
A. Gianetti
Author:
T. Bieber
Author:
J. Vyas
Author:
M. Deleuran
Corporate Author: European Tacrolimus Ointment Study Group
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics